Acute Myeloid Leukemia and Myelodysplastic Syndromes
HOVON supports clinical research in newly diagnosed and relapsed acute myeloid leukemia, including molecularly defined disease with NPM1, IDH1, IDH2, and FLT3 alterations. Its portfolio also includes myelodysplastic syndrome and MDS-EB2, with interest in treatment-resistant and unfit patient populations.
- Targeted therapy in molecularly defined AML
- Combination regimens for newly diagnosed disease
- Maintenance strategies in AML and MDS
Research activity in this area spans intensive and non-intensive treatment settings, with attention to remission depth, survival outcomes, and disease control in older or medically complex patients.
Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The sponsor is active in CLL and SLL, including relapsed, refractory, and first-line disease. Its studies focus on immune-based and targeted approaches such as venetoclax, BTK inhibitors, and CD20-directed therapy, with emphasis on measurable residual disease and durable disease control.
- Relapsed or refractory CLL/SLL
- Minimal residual disease eradication
- Fixed-duration and maintenance treatment
Research also includes patients with prior exposure to venetoclax and those not suited to intensive regimens, reflecting a strong focus on treatment sequencing in chronic B-cell malignancies.
Lymphoma and Central Nervous System Lymphoma
HOVON funds studies across aggressive and indolent lymphoma subtypes, including diffuse large B-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, and non-Hodgkin lymphoma. The research portfolio also covers primary central nervous system lymphoma and secondary CNS lymphoma.
- Relapsed and refractory lymphoma
- Consolidation and salvage treatment
- CNS-involved B-cell malignancies
Key interests include antibody-based therapies, immunotherapy, and strategies aimed at improving disease control after induction or in high-risk relapse settings.
Multiple Myeloma and Waldenström’s Macroglobulinemia
The sponsor has an active research presence in multiple myeloma, smoldering multiple myeloma, and relapsed or refractory Waldenström’s macroglobulinemia. These trials explore both early disease management and treatment for recurrent disease.
- Smoldering and symptomatic myeloma
- Relapsed Waldenström’s macroglobulinemia
- Immune and targeted treatment approaches
Investigations in this area include regimens designed to deepen response and extend disease control in plasma cell and lymphoplasmacytic disorders.
Myelofibrosis and Cold Agglutinin Disease
HOVON also studies rarer hematologic conditions such as myelofibrosis, including primary and post-polycythemia vera or post-essential thrombocythemia forms, as well as cold agglutinin disease. These programs address patients with limited treatment options and persistent symptom burden.
- JAK inhibitor-refractory myelofibrosis
- Spleen volume reduction in myelofibrosis
- Complement- and B-cell-directed therapy in cold agglutinin disease
This area reflects interest in chronic marrow disorders and immune-mediated hemolytic disease, with attention to symptom relief and hematologic response.
